Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Tumor necrosis factor-alpha Stories

2012-04-23 20:20:01

Tokyo, Apr 23, 2012 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) that the condition for approval of Humira(R) pre-filled syringe 40 mg/0.8 mL for subcutaneous injection (adalimumab [genetical recombination]), a fully human anti-TNF-alpha monoclonal antibody, has been lifted in terms of a drug use results survey (all-case surveillance) for plaque psoriasis and...

2012-04-12 22:25:16

Researchers at Boston University School of Medicine (BUSM) have identified a gene that plays a key role in regulating inflammatory response and homeostasis. These findings could help lead to the development of innovative methods to reduce the inflammation associated with cancer, type 2 diabetes and other diseases. The study, which was led by Valentina Perissi, PhD, assistant professor of biochemistry at BUSM, was done in collaboration with the Howard Hughes Medical Institute (HHMI) at the...

2012-03-20 11:19:01

Hedgehog and mTOR converge; Findings suggest new combination therapy Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs that attack the Hedgehog pathway. A team of researchers at The University of Texas MD Anderson Cancer Center reports in the March 20 Cancer Cell that the mTOR molecular pathway promotes the activity...

2012-02-23 13:26:50

Researchers at National Jewish Health have discovered specific molecular and signaling events by which vitamin D inhibits inflammation. In their experiments, they showed that low levels of Vitamin D, comparable to levels found in millions of people, failed to inhibit the inflammatory cascade, while levels considered adequate did inhibit inflammatory signaling. They reported their results in the March 1, 2011, issue of The Journal of Immunology. “This study goes beyond previous...

2012-02-13 15:04:02

Increase not necessarily linked to arthritis treatments, including TNF inhibitors New research reports that incident malignancy among children with juvenile idiopathic arthritis (JIA) is four times higher than in those without the disease. Findings now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), suggest JIA treatment, such as tumor necrosis factor (TNF) inhibitors, does not necessarily explain the...

2011-12-27 08:46:14

Researchers of VIB and UGent have discovered a new approach to preventing septic shock, an often fatal extreme inflammatory reaction of the body. It is the most frequent cause of death at intensive care departments in hospitals. In sepsis, acute inflammation is attended by low blood pressure and blood clots, causing the organs to stop working. Only recently, the Brazilian football legend Socrates, died of the consequences of this condition. In a new study in the top journal Immunity, Peter...

2011-12-23 00:57:42

Inflammatory signaling blocks NUMB´s ability to deaden NOTCH1-driven tumor development An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell. Working in liver cancer cell lines, the team discovered a mechanism by which tumor necrosis factor alpha (TNFα)...

2011-12-22 15:29:05

Sepsis, a form of systemic inflammation, is the leading cause of death in critically ill patients. Sepsis is linked with massive cell death; however, the specific mechanisms involved in the lethality of sepsis are unclear. Now, a new study published by Cell Press in the December 23rd issue of the journal Immunity finds that inhibition of a specific cell death pathway called "necroptosis" protected mice from lethal inflammation. The research may lead to new therapeutic interventions for fatal...

2011-11-08 05:00:00

ABBOTT PARK, Ill., Nov. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA® (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis (AS). Improvements in disease activity were measured from baseline through year five. At baseline and year five, the study showed mean Bath Ankylosing...

2011-11-05 23:30:00

According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, people taking anti-tumor necrosis factor therapies to treat rheumatoid arthritis have a higher risk of developing malignant melanoma. Chicago, Illinois (PRWEB) November 05, 2011 According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, people taking anti-tumor necrosis factor therapies to treat rheumatoid...